Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

Part of paid clinical trials in New Brunswick, New Jersey.

Sponsor: Rutgers, The State University of New Jersey
Study ID: NCT07643012
Status: Recruiting

Apply to this trial

Conditions

Endometrial Cancer

Eligibility Criteria

Sex: FEMALE
Age: 18 Years - 90 Years
Healthy Volunteers: Not accepted

Interventions

MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) — RADIATION
Participants receive moderately hypofractionated MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) delivered via MR-linac to a total dose of 42 Gy in 15 fractions with daily onboard MRI guidance and online adaptive replanning as needed to optimize target coverage and minimize radiation exposure to surrounding organs at risk.

Study Details

To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.

Key Dates

First listed: Jun 11, 2026
Start date: Jun 9, 2026
Status verified: May 2026
Primary completion: Jun 30, 2029
Completion: Jun 30, 2029

Study Design

Enrollment: 30 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Experimental: MR-guided Adaptive Pelvic IMRT
Participants receive moderately hypofractionated MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) delivered via MR-linac to a total dose of 42 Gy in 15 fractions with daily onboard MRI and online adaptive replanning as needed to optimize target coverage and minimize radiation exposure to surrounding organs at risk. Vaginal brachytherapy may be administered following IMRT at the treating physician's discretion per institutional standards.